Patents by Inventor Ana Isabel Mateo Herranz

Ana Isabel Mateo Herranz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Protein kinase inhibitors
    Patent number: 7855211
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    Type: Grant
    Filed: December 15, 2009
    Date of Patent: December 21, 2010
    Assignee: Eli Lilly and Company
    Inventors: David A Coates, Lawrence Mark Gelbert, John M. Knobeloch, Alfonso De Dios Magana, Ana De Prado Gonzalez, Miriam Filadelfa Del Prado Catalina, Maria Cristina Garcia Paredes, Eva Maria Martin De La Nava, Maria Dolores Martin Ortega Finger, Jose Antonio Martinez Perez, Ana Isabel Mateo Herranz, Carlos Perez Martinez, Concepcion Sanchez Martinez
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20100204207
    Abstract: Compounds of Formula (I): wherein n, m, p, q, Y, R1, R2, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: April 20, 2010
    Publication date: August 12, 2010
    Inventors: Xinchao Chen, Christopher Lawrence Cioffi, Sean Richard Dinn, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Saravanan Parthasarathy, Xiaodong Wang
  • Compounds and methods for treating dislipidemia
    Patent number: 7749992
    Abstract: Compounds of formula I wherein n, m, p, q, y, R1 R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating artherosclerosis and its sequelae.
    Type: Grant
    Filed: October 7, 2004
    Date of Patent: July 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Todd Fields, Douglas Linn Gernert, Christopher Lawrence Cioffi, Robert Jason Herr, Nathan Bryan Mantlo, Eva Maria Martin De La Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • PROTEIN KINASE INHIBITORS
    Publication number: 20100160340
    Abstract: The present invention provides a compound of formula (I): or a pharmaceutically acceptable salt thereof which is useful in the treatment of cell proliferative diseases.
    Type: Application
    Filed: December 15, 2009
    Publication date: June 24, 2010
    Inventors: David A. COATES, Lawrence Mark GELBERT, John M. KNOBELOCH, Alfonso DE DIOS MAGANA, Ana DE PRADO GONZALEZ, Miriam FILADELFA DEL PRADO CATALINA, Maria Cristina GARCIA PAREDES, Eva Maria MARTIN DE LA NAVA, Maria Dolores MARTIN ORTEGA FINGER, Jose Antonio MARTINEZ PEREZ, Ana Isabel MATEO HERRANZ, Carlos PEREZ MARTINEZ, Concepcion SANCHEZ MARTINEZ
  • Compounds and methods for treating dyslipidemia
    Patent number: 7470705
    Abstract: The present invention discloses compounds of formula (I) wherein A, n, q, K, W, X, Y; Z, R1, R2, R3, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed as useful for treating dyslipidemia and its sequelae.
    Type: Grant
    Filed: March 17, 2005
    Date of Patent: December 30, 2008
    Assignee: Eli Lilly and Company
    Inventors: Michael Gregory Bell, Guoqing Cao, Ana Maria Escribano, Maria Carmen Fernandez, Peter Ambrose Lander, Nathan Bryan Mantlo, Eva Maria Martin de la Nava, Ana Isabel Mateo Herranz, Daniel Ray Mayhugh, Xiaodong Wang
  • Compounds and Methods for Treating Dyslipidemia
    Publication number: 20080269284
    Abstract: Compounds of Formula I wherein n, q, Y, R1, R2a, R2b, R3a, R3b, R4, R5, and R6 are as defined herein and their pharmaceutical compositions and methods of use are disclosed.
    Type: Application
    Filed: June 22, 2005
    Publication date: October 30, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Ana Maria Escribano, Maria Carmen Fernandez, Nathan Bryan Mantlo, Ana Isabel Mateo-Herranz, Eva Maria Martin De La Nava, Xiaodong Wang
  • Excitatory amino acid receptor antagonists
    Patent number: 7205313
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Grant
    Filed: December 19, 2001
    Date of Patent: April 17, 2007
    Assignee: Eli Lilly and Company
    Inventors: Thomas John Bleisch, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Melanocortin receptor agonists
    Patent number: 7169777
    Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction
    Type: Grant
    Filed: January 23, 2002
    Date of Patent: January 30, 2007
    Assignee: Eli Lilly and Company
    Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Caño, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie
  • Modulators of acetylcholine receptors
    Patent number: 7148236
    Abstract: The present invention relates to compounds that modulate neurotransmission by promoting the release of neurotransmitters such as acetylcholine, dopamine and norepinephrine. More particularly, the present invention relates to thio-bridged aryl compounds that are capable of modulating acetylcholine receptors and pharmaceutical compositions comprising such compounds. The compounds disclosed are useful for the treatment of dysfunctions of the central and autonomic nervous systems.
    Type: Grant
    Filed: July 29, 2002
    Date of Patent: December 12, 2006
    Assignee: Merck & Co., Inc.
    Inventors: Peter Charles Astles, Stephen Richard Baker, Rowena Villanueva Cube, Jose Antonio Martinez-Perez, Ana Isabel Mateo Herranz, Jean Michel Vernier, Colin Peter Dell, Sonia Gutierrez, Lourdes Prieto, Martine Keenan, Adam Jan Sanderson, Colin William Smith
  • Excitatory amino acid receptor antagonists
    Publication number: 20040138254
    Abstract: The present invention provides novel compounds of Formula (I) and Formula (I(a)), or the pharmaceutically acceptable salts thereof; methods for treating neurological disorders and neurodegenerative diseases, particularly pain and migraine, comprising administering a compound of Formula (I) or Formula (I(a)); and processes for preparing compounds of Formula (I) or Formula (I(a)).
    Type: Application
    Filed: December 1, 2003
    Publication date: July 15, 2004
    Inventors: Macklin Brian Arnold, Thomas John Bleisch, Ana Maria Castano Mansanet, Esteban Dominguez-Manzanares, Jose Antonio Martinez-Perez, Ana Maria Escribano, Ana Isabel Mateo Herranz, Paul Leslie Ornstein, Mark Alan Winter, Scott Allan May, Andrew Michael Ratz, Thomas Michael Wilson
  • Melanocortin receptor agonists
    Publication number: 20040116699
    Abstract: The present invention relates to melanocortin receptor agonist of the formula I useful in the treatment of obesity, diabetes, and male and/or female sexual dysfunction 1
    Type: Application
    Filed: July 11, 2003
    Publication date: June 17, 2004
    Inventors: Ryan Thomas Backer, Karin Briner, Ivan Collado Cano, Oscar De Frutos Garcia, Christopher William Doecke, Matthew Joseph Fisher, Cristina Garcia-Paredes, Steven Lee Kuklish, Vincent Mancuso, Michael John Martinelli, Ana Isabel Mateo Herranz, Jeffrey Thomas Mullaney, Paul Leslie Ornstein, Zhipei Wu, Chaoyu Xie